* CERENIS THERAPEUTICS *
2004 - Midi-Pyrénées
Labège
(near Toulouse)
www.cerenis.com Discovery, Drugs
Key words: HDL therapy, Cholesterol, Atherosclerosis, Cardiovasculars
Mission: to discover, develop and market next generation HDL therapies
Clients: Prescribers
info@cerenis.com
Age: 7 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO: Dasseux (Jean-Louis) [co-founder, born 1958, Ph.D., MBA, ex-Esperion Therapeutics (Pfizer), Fournier]
Oper.Dir.-COO: Brinkerhoff (William) [co-founder, MBA, ex-Esperion Therapeutics (Pfizer), Sankyo]
Sc.Dir.-CSO: Lalwani (Narendra D.) [Ph.D., MBA, ex-Parke Davis, Esperion, Pfizer]
Fin.Dir.-CFO: Tupin (Cyrille) [CPA, ex-Sygnatures, PricewaterhouseCoopers]
Med.Dir.-CMO: Scott (Rob) [M.D., ex-AtheroGenics, Pfizer]
BusDev: Brya (Tom) [MBA (Northwestern), MST, CPA, ex-Pharmacia, Monsanto/Searle, Cardinal Health, KV Pharmaceutical]
Financers (Hist.): Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures, Daiwa Corporate Investment, TVM Capital, OrdiMed, FSI, Irdi-IXO | Turnover (M€) : n.a.
Total funding (M€) : 117.0
Last funding (M€) : 50.0
Focus : Cardiovasc
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .03 | Clinical trial (phase II) for CER-001, in acute coronary syndrome (beginning) | CLIN | [6 years] |
| 2010 .07 | 3rd round-financing : 40.0 M€, half by FSI, half by previous shareholders, Sofinnova Partners, HealthCap, Alta Partners et TVM Capital, EDF Ventures, Orbimed and Daiwa (completed in October by 10.0 M€ additional from Irdi-IXO and private investors) | RFINC | [6 years] |
| 2010 .05 | Clinical trial (phase I) for CER-001, a new drug for acute coronary syndrome (completed) | CLIN | [6 years] |
| 2010 .06 | Financing (no interest loan) : 10.7 M€ by OSEO Innovation, shared with Novasep, to finance the development of CER-001, an HDL-mimetic innovative drug | DEBT | [6 years] |
| 2009 .02 | Financing (no interest loan) : 2.5 M€ by OSEO Innovation, to finance ongoing clinical development of HDL-related products for the treatment of cardiovascular and metabolic diseases | DEBT | [4 years] |
| 2008 .05 | Clinical trial (phase I) for CER-002, a peroxisome proliferator-activated receptor (PPAR) delta specific agonist (completed) | CLIN | [4 years] |
| 2006 .11 | 2nd round-financing : 42.0 M€, led by TVM Capital, with Orbimed and previous shareholders (53.5 MUS$) | RFINB | [2 years] |
| 2005 .08 | 1st round-financing : 25.0 M€, by Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures | RFINA | [1 year] |
| 2004 .05 | Company founded by Jean-Louis Dasseux and William Brinkerhoff | ORGF | [0 year] | Actualisation / Updating: 21-Sep-2011 |
|
